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Abstract
BACKGROUND & AIMS—Heritable factors contribute to the development of colorectal cancer.
Identifying the genetic loci associated with colorectal tumor formation could elucidate the
mechanisms of pathogenesis.
METHODS—We conducted a genome-wide association study that included 14 studies, 12,696
cases of colorectal tumors (11,870 cancer, 826 adenoma), and 15,113 controls of European
descent. The 10 most statistically significant, previously unreported findings were followed up in
6 studies; these included 3056 colorectal tumor cases (2098 cancer, 958 adenoma) and 6658
controls of European and Asian descent.
RESULTS—Based on the combined analysis, we identified a locus that reached the conventional
genome-wide significance level at less than 5.0 × 10−8: an intergenic region on chromosome
2q32.3, close to nucleic acid binding protein 1 (most significant single nucleotide polymorphism:
rs11903757; odds ratio [OR], 1.15 per risk allele; P = 3.7 × 10−8). We also found evidence for 3
additional loci with P values less than 5.0 × 10−7: a locus within the laminin gamma 1 gene on
chromosome 1q25.3 (rs10911251; OR, 1.10 per risk allele; P = 9.5 × 10−8), a locus within the
cyclin D2 gene on chromosome 12p13.32 (rs3217810 per risk allele; OR, 0.84; P = 5.9 × 10−8),
and a locus in the T-box 3 gene on chromosome 12q24.21 (rs59336; OR, 0.91 per risk allele; P =
3.7 × 10−7).
CONCLUSIONS—In a large genome-wide association study, we associated polymorphisms
close to nucleic acid binding protein 1 (which encodes a DNA-binding protein involved in DNA
repair) with colorectal tumor risk. We also provided evidence for an association between
colorectal tumor risk and polymorphisms in laminin gamma 1 (this is the second gene in the
Peters et al. Page 2
Gastroenterology. Author manuscript; available in PMC 2014 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
laminin family to be associated with colorectal cancers), cyclin D2 (which encodes for cyclin D2),
and T-box 3 (which encodes a T-box transcription factor and is a target of Wnt signaling to β-
catenin). The roles of these genes and their products in cancer pathogenesis warrant further
investigation.
Keywords
Colon Cancer; Genetics; Risk Factors; SNP
Colorectal cancer has a sizable heritable component; a large twin study estimated that 35%
of colorectal cancer risk may be explained by heritable factors.1 Over the past several years,
genome-wide association studies (GWAS), which focus on common single-nucleotide
polymorphisms (SNPs), successfully have discovered low-penetrance loci for colorectal
cancer.2–12 These analyses have highlighted genes within the known transforming growth
factor-β and Wnt signaling pathways (eg, bone morphogenetic protein 2 & 4, SMAD7), as
well as regions and genes not previously strongly implicated in colorectal cancer (eg, zinc
finger protein 90, laminin alpha 5, disco-interacting protein 2), thereby highlighting
pathways previously not understood to be involved in colorectal carcinogenesis.2–12
To identify additional common genetic risk factors for colorectal tumors, we conducted a
genome-wide scan across 14 independent studies including nearly 28,000 subjects and
follow-up evaluation of nearly 10,000 independent subjects. We included both colorectal
cancer cases and colorectal adenoma cases. Colorectal adenoma is a well-defined colorectal
cancer precursor13 and the majority of colorectal cancers develop through the adenoma-
cancer sequence.14 It has been estimated that the 10-year cumulative rate for advanced
adenoma to transition to colorectal cancer is between 10% and 45%, depending on age and
sex.13,15,16 Accordingly, the 2 phenotypes have overlapping etiology.17 Inclusion of
adenoma cases can increase sample size, and hence statistical power, to identify genetic risk
factors related to early events in the adenoma-carcinoma process, during which risk factor
intervention strategies may offer the greatest potential benefit for cancer prevention.
Materials and Methods
Study Participants
Each study is described in detail in the Supplementary Materials and Methods section and
the number of cases and controls as well as age and sex distributions are listed in
Supplementary Table 1. In brief, colorectal cancer cases were defined as colorectal
adenocarcinoma and confirmed by medical records, pathologic reports, or death certificate.
Colorectal adenoma cases were confirmed by medical records, histopathology, or pathologic
reports. Controls for adenoma cases had a negative colonoscopy (except for the Nurses’
Health Study and the Health Professionals Follow-up Study controls matched to cases with
distal adenoma, which either had a negative sigmoidoscopy or colonoscopy examination).
All participants provided written informed consent and studies were approved by their
respective institution’s Institutional Review Boards.
Genotyping
GWAS in the Genetics and Epidemiology of Colorectal Cancer Consortium
and the Colon Cancer Family Registry—We conducted a meta-analysis of GWAS
from 13 studies within the Genetics and Epidemiology of Colorectal Cancer Consortium
(GECCO) (10,729 cases and 13,328 controls) and additional GWAS within the Colon
Cancer Family Registry (CCFR) (1967 cases and 1785 controls). Details on genotyping,
quality assurance/quality control, and imputation can be found in the Supplementary
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Materials and Methods section. Average sample and SNP call rates and concordance rates
for blinded duplicates are listed in Supplementary Table 2. In brief, all analyses were
restricted to European ancestry. Genotyped SNPs were excluded based on call rate (<98%),
lack of Hardy–Weinberg equilibrium in controls (HWE, P < 1 × 10−4), and low minor allele
frequency (MAF). Because imputation of genotypes is established as standard practice in the
analysis of genotype array data, we imputed the autosomal SNPs of all studies to the Utah
residents with Northern and Western European ancestry from the Centre d’etude du
polymorphisme humain (CEPH) collection (CEU) population in HapMap II (available at:
http://hapmap.ncbi.nlm.nih.gov/). Imputed SNPs were restricted based on MAF (≥1%) and
imputation accuracy (R2 > 0.3). After imputation and quality control (QC), a total of
2,708,280 SNPs were used in the meta-analysis of GECCO studies and CCFR. In our
detailed result table (Supplementary Table 3), we list for each SNP the number of studies
with directly genotyped or imputed data and the mean imputation R2. These data show, as
expected, that imputed SNPs tend to show very similar results as SNPs that were directly
genotyped if the correlation is high between SNPs.
Follow-up studies—We selected the 10 most statistically significant regions (excluding
known GWAS loci) based on the P value from the GECCO and CCFR meta-analysis for
further follow-up evaluation in colorectal cancer studies in the Asian colorectal cancer
consortium and a US-based colorectal adenoma study. Details on genotyping, quality
assurance/quality control, and imputation can be found in the Supplementary Materials and
Methods section. After quality control exclusions, 2098 colorectal cancer cases and 5749
controls, and 958 colorectal adenoma cases and 909 controls remained in the analysis.
Statistical Analysis
GWAS in GECCO and CCFR—Statistical analyses of the GECCO and CCFR samples
were conducted centrally at the coordinating center on individual-level data to ensure a
consistent analytic approach. For each study, we estimated the association between SNPs
and risk for colorectal cancer by calculating β values, odds ratios (ORs), standard errors,
95% confidence intervals, and P values using logistic regression models with log-additive
genetic effects. Each directly genotyped SNP was coded as 0, 1, or 2 copies of the risk
allele. For imputed SNPs, we used the expected number of copies of the risk allele (the
dosage), which has been shown to provide unbiased estimates in the association test for
imputed SNPs.18 We adjusted for age, sex (when appropriate), center (when appropriate),
smoking status (Physicians’ Health Study only), batch effects (The french Association
STudy Evaluating RISK for sporadic colorectal cancer), and the first 3 principal components
from EIGENSTRAT (available at: http://genepath.med.harvard.edu/~reich/
EIGENSTRAT.htm) to account for population substructure. Because CCFR set 2 is a
family-based study, we used a conditional logistic regression stratified by family
identification while adjusting for age and sex. When analyzing genotyped SNPs on the X
chromosome we need to account for different genotype variances between males and
females. Therefore, we used the 1 degree of freedom modified Cochran–Armitage test19 to
test for associations. This method has been shown to have robust and powerful performance
across a wide range of scenarios.20 We used logistic regression to model SNP × SNP
interaction effects for a log-additive model, in which the interaction term is the product of
the 2 SNPs.
Quantile-quantile plots were assessed to determine whether the distribution of the P values
in each study was consistent with the null distribution (except for the extreme tail). We also
calculated the genomic inflation factor (λ) to measure the overdispersion of the test statistics
from the association tests by dividing the median of the squared Z statistics by 0.455, the
median of a chi-squared distribution with 1 degree of freedom. The inflation factor λ was
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between 0.999 and 1.044 for individual studies based on all SNPs including both directly
genotyped and imputed, indicating there is little evidence of residual population
substructure, cryptic relatedness, or differential genotyping between cases and controls. This
result was consistent with the visual inspection of the study-specific quantile-quantile plots.
We conducted inverse-variance weighted, fixed-effects meta-analysis to combine β
estimates and standard errors across individual studies. In this approach, we weighed the β
estimate of each study by its inverse variance and calculated a combined estimate by
summing the weighted β estimates and dividing by the summed weights. For imputed SNPs,
it has been shown that the inverse variance is approximately proportional to the imputation
quality.18 Thus, the inverse variance weighting scheme automatically incorporates
imputation quality in the meta-analysis for imputed SNPs. We calculated the heterogeneity P
values based on Cochran’s Q statistic21 and investigated sources for heterogeneity if the P
value was less than .05 for the 10 most significant SNPs. For the most significant SNPs
highlighted in this article, we also examined recessive and unrestricted genetic models and
compared models by calculating the Akaike information criterion. We used PLINK
(available at: pngu.mgh.harvard.edu/~purcell/plink/)22 and R (available at: http://www.r-
project.org/)23 to conduct the statistical analysis and summarized results graphically using
LocusZOOM (available at: http://csg.sph.umich.edu/locuszoom/).24
Follow-up studies—The 10 most significant SNPs from the GWAS meta-analysis
described earlier were analyzed in the follow-up studies (P values from GWAS meta-
analysis 2.5 × 10−7 to 6.5 × 10−6). For the Asian colorectal cancer follow-up study,
genotyped SNPs and dosage data of imputed SNPs were analyzed using the program
mach2dat (available at: http://www.sph.umich.edu/csg/abecasis/MACH/download/).25 The
association between SNP and colorectal cancer risk was assessed using logistic regression
with log-additive genetic effects after adjusting for age and sex. Meta-analyses were
performed using the inverse-variance method based on a fixed-effects model, and
calculations were implemented in the METAL package (available at: http://
www.sph.umich.edu/csg/abecasis/metal/).26 Because the MAF in the Asian follow-up
population was very low for the locus on chromosome 14q23.1 (MAF, 0 – 0.006 in Han
Chinese individuals from Beijing, China), we excluded this SNP from the follow-up
evaluation in the Asian studies. Given potential differences in the linkage disequilibrium
structure between European and Asian descent subjects, we also included all SNPs
correlated with these 10 selected SNPs (r2 > 0.5 in CEU).
For the adenoma follow-up study (all European descent), the association between each
genetic marker and risk for colorectal adenoma was estimated by calculating ORs and 95%
confidence intervals, using a log-additive genetic model. SNPTESTv2.2.0 (available at:
https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html) with the “-method
score” option27 was used for logistic regression with the frequentist test, and the model was
adjusted for age and sex.
For a combined analysis of GWAS and follow-up results, we conducted inverse-variance
weighted fixed-effects meta-analysis to combine ORs from log-additive models across
individual studies and measured heterogeneity using Cochran’s Q statistic, as discussed
earlier.
Criterion for genome-wide significance—Based on an increasing number of
articles28–33 providing a detailed discussion on the appropriate genome-wide significance
threshold, which all arrive at similar values in the range of 5 × 10−7 to 5 × 10−8 for
European populations, we decided to use a P value of 5 × 10−8 as the genome-wide
significance threshold. In addition, we reported on SNPs with P values between less than 5 ×
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10−7 and greater than 5 × 10−8 as a potentially novel SNP that merited additional follow-up
evaluation.
Heritability estimates—We estimated the additive heritability of colorectal cancer
explained by all genotyped SNPs using the method by Yang et al34 and implemented in the
Genome-wide Complex Trait Analysis tool.35 We set the prevalence of colorectal cancer to
0.004, based on Surveillance, Epidemiology and End Results incidence and National Center
for Health Statistics mortality statistics.36 We used all genotyped SNPs of Darmkrebs:
Chancen der Verhütung durch Screening set II and Diet, Activity, and Lifestyle Study set I
given the sizable sample set, different genotyping platforms, and inclusion of both sexes
(Supplementary Table 1). We also estimated the heritability of previously and newly
identified variants by using the method of So et al.37 Furthermore, we used the method
described by Park et al38 to estimate the total number of loci expected to be identified for
colorectal cancer based on the observed effect sizes and power for identifying the loci
known to date (Table 1 and Supplementary Table 4).
Functional annotation of findings—We conducted a functional annotation for all
tagging SNPs (and correlated SNPs) highlighted in this article. As detailed in the
Supplementary Materials and Methods section, we queried multiple bioinformatic databases
based on the University of California, Santa Cruz genome browser.
Results
Summary results of the GWAS meta-analysis of GECCO and CCFR are shown in the
Manhattan plot (Supplementary Figure 1). Several of the previously identified GWAS SNPs
were highly significantly associated with colorectal cancer, and overall we found a nominal
significant association (P < .05) in the same direction for 16 of 18 previously identified
GWAS loci (Supplementary Table 4). After excluding previously identified regions, we
followed up the 10 most significant regions from the GWAS meta-analysis (P = 2.5 × 10−7
to 6.5 × 10−6; Supplementary Table 3). In 4 regions the follow-up studies showed evidence
of replication with the association in the same directions as the GWAS and an overall
improved significance level (Table 1). Of these 4 regions, 1 region reached the conventional
genome-wide significance level at a P value less than 5.0 × 10−8 in the combined analysis
(GWAS + follow-up evaluation). This region was on chromosome 2q32.3 (rs11903757: OR,
1.16 per risk allele; P = 3.7 × 10−8; Table 1 and Supplementary Figure 2). The SNP showed
no evidence for heterogeneity (P = .27) across all studies. The SNP was correlated strongly
(r2 > 0.9) with several SNPs in the same region, which showed similar results
(Supplementary Figure 3 and Supplementary Table 3).
The other 3 regions had P values less than 5.0 × 10−7 (and P > 5.0 × 10−8) in the combined
analysis (GWAS + follow-up evaluation). Reporting by chromosomal position, the first of
these 3 regions was on chromosome 1q25.3. In this region, the association with rs10911251
had the lowest P value (OR, 1.09 per risk allele; P = 9.5 × 10−8; Table 1 and Supplementary
Figure 2), showing no evidence of heterogeneity (P = .69) across studies. This was
correlated strongly with a large number of SNPs in the same region showing similar allele
frequencies, risk estimates, and P values spanning across the entire laminin gamma 1
(LAMC1) gene (Supplementary Figure 3 and Supplementary Table 3).
The second region with P values less than 5.0 × 10−7 and greater than 5.0 × 10−8 was on
chromosome 12p13, within the cyclin D2 (CCND2) gene. The most statistically significant
SNP was rs3217810 (OR, 1.20 per risk allele; P = 5.9 × 10−8; Table 1 and Supplementary
Figure 2). Furthermore, only 17.1 kb apart resides a second SNP, rs3217901, which was not
strongly correlated with rs3217810 (r2 = 0.052 – 0.063) and showed a slightly lower
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significance level (OR, 1.10 per risk allele; P = 4.9 × 10−7). Although the risk allele
frequency of rs3217810 in our European descent studies was on average 0.16, this SNP is
very uncommon in Asian populations (0.03 in Japanese in Tokyo, Japan, and 0.01 in Han
Chinese individuals from Beijing, China) and, hence, the follow-up evaluation of rs3217810
did not include the Asian cases and controls. Both SNPs were not heterogeneous across
studies (P for heterogeneity = .51 and .91). When we included both SNPs simultaneously in
the logistic regression analysis the significance of both SNPs was reduced (Supplementary
Table 5).
The third region with P values less than 5.0 × 10−7 was in the T-box 3 (TBX3) gene on
chromosome 12q24.21. The most statistically significant SNP in this region was rs59336
(OR, 1.09 per risk allele; P = 3.7 × 10−7; Table 1 and Supplementary Figure 2). Again, we
observed no evidence for heterogeneity across studies (P = .39).
We investigated if the 4 regions listed earlier might be more significant (lower P value)
under a different genetic model than the log-additive model. None of the variants was more
significant when we modeled the unrestricted, dominant, or recessive mode of inheritance
(Supplementary Table 6).
When we stratified results by colorectal adenoma and cancer we observed stronger
associations for adenoma compared with cancer for rs11903757 at 2q32.3, similar
associations for rs3217810 and rs3217901 at 12p13/CCDN2 and for rs59336 at 12q24.21/
TBX3, and a weaker association for rs10911251 at 1q25.3/LAMC1 (Supplementary Table
7). For previously identified loci, in particular, associations for rs16892766 at 8q23.3/EIF3H
and rs4939827 at 18q21/SMAD7 tended to be stronger for adenoma, whereas associations
for other loci tended to be similar or weaker compared with cancer (Supplementary Table 4).
We observed no evidence for interaction between the SNPs in the newly identified regions
or with SNPs in previously identified regions. The smallest P value for interaction was .017
for rs59336/TBX3 and rs11632715/15q13 and was not significant after accounting for
multiple comparisons.
As popularized by Yang et al,34 we estimated that the additive heritability of colorectal
cancer explained by all genotyped SNPs would be 14.2% (standard error, 8.2%). The newly
identified loci (Table 1) and previously identified loci (Supplementary Table 4) explained
about 11% of the additive heritability and cumulatively these newly and previously
identified loci explain 1.6% of the variation of colorectal cancer. Based on the study by Park
et al38 we estimated that the total number of loci expected to be identified for colorectal
cancer would be between 239 and 500 if the type I error rate was between 5 × 10−7 and 5 ×
10−8.
Discussion
In this large genome-wide scan meta-analysis and follow-up evaluation of a total of close to
38,000 subjects, we identified an intergenic region on chromosome 2q32.3 close to nucleic
acid binding protein 1 (NABP1) that was associated with colorectal tumor risk with P values
less than 5.0 × 10−8, the conventional genome-wide significance level. Furthermore, we
identified 3 regions with P values less than 5.0 × 10−7: one on chromosome 1q31 in
LAMC1, a second on chromosome 12p13 in CCND2, and a third on chromosome 12q24.21
in TXB3. All showed highly significant associations with P values less than 5 × 10−7.
Our study provides strong support for an intergenic locus on chromosome 2q32.3. The most
significant SNPs in this region are in closest proximity to the NABP1 gene (44 kb
centromeric) and the gene serum deprivation response (112 kb telomeric), which encodes for
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the serum-deprivation response phosphatidylserine-binding protein. The SNPs are
downstream of NABP1, which also is known as human single-strand DNA binding protein 2
or oligonucleotide/oligosaccharide binding fold-containing protein 2A. This protein binds
single-stranded DNA via the oligonucleotide/oligosaccharide binding fold domain.39 Single-
stranded DNA binding proteins are important for diverse DNA processes, such as DNA
replication, recombination, transcription, and repair.40–42 Cells depleted of NABP1 show
hypersensitivity to DNA-damaging reagents; NABP1 participates in repair of DNA double-
strand breaks and ataxia telangiectasia mutated–dependent signaling pathways,43 similar to
the role of its homolog, NABP2 (which is also known as human single-strand DNA binding
protein 1).39 Although our functional annotation did not provide further insights on the
function of the SNPs, the biologic data described earlier support the importance of NABP1
with respect to genomic stability, which could explain a link to the development of cancer.44
In addition to the genome-wide significant region we observed 3 regions that were slightly
less significant with P values less than 5 × 10−7 but greater than 5 × 10−8. As has been
shown previously,45 a large fraction of SNPs with borderline genome-wide–significant
associations replicated when results from additional studies were added, suggesting that
further follow-up evaluation of these regions is warranted. The first of these 3 regions was
on chromosome 1q31 and included correlated SNPs showing associations that spanned
across the LAMC1 gene. Interestingly, previous genome-wide scans of colorectal cancer
identified a different laminin gene on chromosome 20q13.33, laminin alpha 5, as associated
with colorectal cancer,9,11 supporting the importance of this gene family for the
development of colorectal cancer. Laminins are extracellular matrix glycoproteins that
constitute a major component of the basement membrane in most tissues46 and in the colon
are part of the intestinal epithelial barrier. Laminins are involved in a wide variety of
biological functions, such as regulation of cell adhesion, differentiation, migration,
signaling, and metastasis.47–50 Loss of cell-surface laminin anchoring has been found in
many cancer cells, particularly those with aggressive subtypes.51
LAMC1 is a large gene spanning 122 kb and containing 28 coding exons. rs10911251 is
correlated strongly (r2 > 0.8) with several other SNPs across the gene (Supplementary
Figure 3 and Supplementary Table 3). Upon functional annotation, we identified a potential
functional candidate (rs10911205) that is correlated strongly with the most significant
tagSNP (r2 = 0.73) and located 72 kb upstream within the first intron of LAMC1. As shown
in the University of California, Santa Cruz Genome Browser view (Supplementary Figure
4), rs10911205 is located within a highly evolutionarily conserved region and, given its
close proximity to the promoter, it is possible that this region influences gene transcription.
In addition, the patterns of histone modifications and DNase signals indicating accessibility
for transcription factors suggest that this variant may affect cell-type–specific enhancer
activity. In summary, given the statistical evidence, support from functional annotation, and
evidence from a previous GWAS that identified another laminin gene to be associated with
colorectal cancer, we believe there is strong support for the importance of LAMC1 in the
development of colorectal cancer. It is of note that the biologic role of this gene family has
not yet been studied substantially in relation to colorectal cancer, supporting the novelty of
this finding.
A second region with P values less than 5 × 10−7 was on chromosome 12p13.32, with 2
independent SNPs both located in the intron of CCND2, which belongs to the highly
conserved cyclin family, specifically encoding for the protein cyclin D2. Through regulation
of CDK4 and CDK6, cyclin D2 affects the cell-cycle transition of the G1/S phase.52,53
Furthermore, cyclin D2 interacts with tumor-suppressor protein retinoblastoma. Recent
studies have identified CCND2 as an microRNA target gene in different colorectal cancer
cell lines.54,55 Interestingly, genetic variants in CCND1 also have been related to colorectal
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cancer56,57 and a previous GWAS identified a SNP in CCND1 to be associated with breast
cancer.58
The third region with P values less than 5 × 10−7 we identified was within the TBX3 gene,
which encodes the T-box transcription factor. TBX3 is overexpressed in several cancers,
including pancreas, liver, breast cancer, and melanoma,59 playing multiple roles in normal
development and cancer.60 In liver cancer, TBX3 was identified as a downstream target of
the Wnt/β-catenin pathway, mediating β-catenin activities on cell proliferation and
survival.61 The Wnt/β-catenin pathway plays a key role in colorectal cancer development.62
TBX5, another member of the T-Box gene family, has been suggested as an epigenetically
inactivated tumor-suppressor gene in colon cancer63 and provides an additional mechanism
by which this gene family may influence colorectal cancer development.
Our study adds further support for all, except 3, previously identified GWAS loci for
colorectal cancer. The 3 SNPs (on chromosomes 1q41, 3q26.2, and 6p21) that did not
replicate are among the more recently identified GWAS loci9,12 and have smaller effect
sizes (OR for risk allele, ≤1.1) compared with the earlier GWAS findings. As a result, larger
sample sizes may be needed to fully replicate these SNPs. Furthermore, it is possible that the
effect varies by environmental exposures, which may differ among the study populations.
Overall, effect sizes from our study for previous GWAS loci tend to be weaker than in the
initial reports, which may be explained by the fact that previous results were subject to the
“winner’s curse.”64
The large sample size of our GWAS and follow-up studies and availability of individual-
level GWAS data are important advantages of our study. However, the study also had
limitations. To increase the sample size, we included Asian descent subjects, who may have
different linkage disequilibrium patterns, and the SNPs analyzed may be tagging different
underlying causal variants. To address this potential limitation we included all SNPs
correlated with the most significant SNPs, which likely will identify any variant that
genuinely is associated with colorectal cancer risk across different ancestral groups, as
shown for other GWAS loci.65–68 Given that genotyping platforms only capture a subset of
the genome, we used imputation to HapMap II to obtain a better coverage of the common
variation across the genome and to generate a common set of SNPs from the different
platforms. Because imputed SNPs tend to result in less significant findings depending on
their imputation accuracy,69 we expect that our results provide relative conservative
significance levels.70 Similar to previous GWAS,2,4,6–10,12 we included colorectal adenoma
as the major precursor of colorectal cancer to improve our statistical power and to identify
genetic variants that act early in the adenoma-cancer sequence, where adenomas and cancer
have a shared etiology. Although the inclusion of adenoma also may add heterogeneity
because adenomas will not show an association for genetic variants that act later in the
carcinogenic process (ie, on progression from adenoma to cancer) or for variants that act
through adenoma-independent pathways, stratified analysis may provide insights into the
mediating roles of genes within the normal to adenoma to cancer pathway. We show that for
some of the newly and previously identified loci, associations are stronger for adenomas
compared with cancer; however, we observed similar or weaker associations for other loci.
These results may suggest that some genes are important in early stages of cancer
development while others may be more important for the progression from adenoma to
cancer. However, given the relatively small number of adenoma cases (only 6.5% of the
GWAS and 31% of the follow-up cases were adenoma cases), it is important that our
findings are replicated in studies with larger numbers of adenoma cases.
In summary, in this large study, we identified one novel susceptibility locus associated with
the risk of colorectal tumor on chromosome 2q32.3 close to NABP1, and 3 potential loci
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with borderline genome-wide significant results within LAMC1, CCND2, and TBX3. These
findings are supported by biologic plausibility, functional annotation, and previous GWAS
findings within the same gene family, emphasizing the potential relevance of these genes in
the etiology of colorectal cancer.
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Refer to Web version on PubMed Central for supplementary material.
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Abbreviations used in this paper
CFR Colon Cancer Family Registry
CCND cyclin D2
CEU Utah residents with Northern and Western European ancestry from the CEPH
collection
CEPH Centre d’etude du polymorphisme humain
GECCO Genetics and Epidemiology of Colorectal Cancer Consortium
GWAS genome-wide association study
HWE Hardy Weinberg Equilibrium
LAMC1 laminin gamma 1
MAF minor allele frequency
NABP1 nucleic acid binding protein 1
ORs odds ratios
QC quality control
SNP single nucleotide polymorphism
TBX3 T-box 3
References
1. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation
of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;
343:78–85. [PubMed: 10891514]
2. Tomlinson I, Webb E, Carvajal-Carmona L, et al. A genome-wide association scan of tag SNPs
identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet. 2007; 39:984–988.
[PubMed: 17618284]
3. Zanke BW, Greenwood CM, Rangrej J, et al. Genome-wide association scan identifies a colorectal
cancer susceptibility locus on chromosome 8q24. Nat Genet. 2007; 39:989–994. [PubMed:
17618283]
4. Broderick P, Carvajal-Carmona L, Pittman AM, et al. A genome-wide association study shows that
common alleles of SMAD7 influence colorectal cancer risk. Nat Genet. 2007; 39:1315–1317.
[PubMed: 17934461]
5. Tenesa A, Farrington SM, Prendergast JG, et al. Genome-wide association scan identifies a
colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat
Genet. 2008; 40:631–637. [PubMed: 18372901]
6. Jaeger E, Webb E, Howarth K, et al. Common genetic variants at the CRAC1 (HMPS) locus on
chromosome 15q13.3 influence colorectal cancer risk. Nat Genet. 2008; 40:26–28. [PubMed:
18084292]
7. Tomlinson IP, Webb E, Carvajal-Carmona L, et al. A genome-wide association study identifies
colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet. 2008; 40:623–
630. [PubMed: 18372905]
8. Houlston RS, Webb E, Broderick P, et al. Meta-analysis of genome-wide association data identifies
four new susceptibility loci for colorectal cancer. Nat Genet. 2008; 40:1426–1435. [PubMed:
19011631]
9. Houlston RS, Cheadle J, Dobbins SE, et al. Meta-analysis of three genome-wide association studies
identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat
Genet. 2010; 42:973–977. [PubMed: 20972440]
Peters et al. Page 12
Gastroenterology. Author manuscript; available in PMC 2014 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
10. Tomlinson IP, Carvajal-Carmona LG, Dobbins SE, et al. Multiple common susceptibility variants
near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of
colorectal cancer. PLoS Genet. 2011; 7:e1002105. [PubMed: 21655089]
11. Peters U, Hutter CM, Hsu L, et al. Meta-analysis of new genome-wide association studies of
colorectal cancer risk. Hum Genet. 2012; 131:217–234. [PubMed: 21761138]
12. Dunlop MG, Dobbins SE, Farrington SM, et al. Common variation near CDKN1A, POLD3 and
SHROOM2 influences colorectal cancer risk. Nat Genet. 2012; 44:770–776. [PubMed: 22634755]
13. Brenner H, Hoffmeister M, Stegmaier C, et al. Risk of progression of advanced adenomas to
colorectal cancer by age and sex: estimates based on 840,149 screening colonoscopies. Gut. 2007;
56:1585–1589. [PubMed: 17591622]
14. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996; 87:159–170.
[PubMed: 8861899]
15. Eide TJ. Risk of colorectal cancer in adenoma-bearing individuals within a defined population. Int
J Cancer. 1986; 38:173–176. [PubMed: 3733258]
16. Stryker SJ, Wolff BG, Culp CE, et al. Natural history of untreated colonic polyps.
Gastroenterology. 1987; 93:1009–1013. [PubMed: 3653628]
17. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst. 1999; 91:916–932.
[PubMed: 10359544]
18. Jiao S, Hsu L, Hutter CM, et al. The use of imputed values in the meta-analysis of genome-wide
association studies. Genet Epidemiol. 2011; 35:597–605. [PubMed: 21769935]
19. Clayton D. Testing for association on the X chromosome. Biostatistics. 2008; 9:593–600.
[PubMed: 18441336]
20. Hickey PF, Bahlo M. X chromosome association testing in genome wide association studies. Genet
Epidemiol. 2011; 35:664–670. [PubMed: 21818774]
21. Ioannidis JP, Patsopoulos NA, Evangelou E. Heterogeneity in meta-analyses of genome-wide
association investigations. PLoS ONE. 2007; 2:e841. [PubMed: 17786212]
22. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and
population-based linkage analyses. Am J Hum Genet. 2007; 81:559–575. [PubMed: 17701901]
23. R Development Core Team. R: a language and environment for statistical computing. Vienna,
Austria: R Foundation for Statistical Computing; 2011.
24. Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: regional visualization of genome-wide
association scan results. Bioinformatics. 2010; 26:2336–2337. [PubMed: 20634204]
25. Li Y, Willer CJ, Ding J, et al. MaCH: using sequence and genotype data to estimate haplotypes and
unobserved genotypes. Genet Epidemiol. 2010; 34:816–834. [PubMed: 21058334]
26. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide
association scans. Bioinformatics. 2010; 26:2190–2191. [PubMed: 20616382]
27. Marchini J, Howie B, Myers S, et al. A new multipoint method for genome-wide association
studies by imputation of genotypes. Nat Genet. 2007; 39:906–913. [PubMed: 17572673]
28. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996;
273:1516–1517. [PubMed: 8801636]
29. International HapMap Consortium. A haplotype map of the human genome. Nature. 2005;
437:1299–1320. [PubMed: 16255080]
30. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of
seven common diseases and 3,000 shared controls. Nature. 2007; 447:661–678. [PubMed:
17554300]
31. Hoggart CJ, Clark TG, De IM, et al. Genome-wide significance for dense SNP and resequencing
data. Genet Epidemiol. 2008; 32:179–185. [PubMed: 18200594]
32. Pe’er I, Yelensk R, Altshuler D, et al. Estimation of the multiple testing burden for genomewide
association studies of nearly all common variants. Genet Epidemiol. 2008; 32:381–385. [PubMed:
18348202]
33. Dudbridge F, Gusnanto A. Estimation of significance thresholds for genomewide association
scans. Genet Epidemiol. 2008; 32:227–234. [PubMed: 18300295]
Peters et al. Page 13
Gastroenterology. Author manuscript; available in PMC 2014 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
34. Yang J, Benyamin B, McEvoy BP, et al. Common SNPs explain a large proportion of the
heritability for human height. Nat Genet. 2010; 42:565–569. [PubMed: 20562875]
35. Yang J, Lee SH, Goddard ME, et al. GCTA: a tool for genome-wide complex trait analysis. Am J
Hum Genet. 2011; 88:76–82. [PubMed: 21167468]
36. Howlader, N.; Noone, AM.; Krapcho, M., et al. SEER cancer statistics review, 1975–2009.
Bethesda, MD: National Cancer Institute; 2012.
37. So HC, Gui AH, Cherny SS, et al. Evaluating the heritability explained by known susceptibility
variants: a survey of ten complex diseases. Genet Epidemiol. 2011; 35:310–317. [PubMed:
21374718]
38. Park JH, Wacholder S, Gail MH, et al. Estimation of effect size distribution from genome-wide
association studies and implications for future discoveries. Nat Genet. 2010; 42:570–575.
[PubMed: 20562874]
39. Richard DJ, Bolderson E, Cubeddu L, et al. Single-stranded DNA-binding protein hSSB1 is critical
for genomic stability. Nature. 2008; 453:677–681. [PubMed: 18449195]
40. Bochkarev A, Bochkareva E, Frappier L, et al. The crystal structure of the complex of replication
protein A subunits RPA32 and RPA14 reveals a mechanism for single-stranded DNA binding.
EMBO J. 1999; 18:4498–4504. [PubMed: 10449415]
41. Wold MS. Replication protein A: a heterotrimeric, single-stranded DNA-binding protein required
for eukaryotic DNA metabolism. Annu Rev Biochem. 1997; 66:61–92. [PubMed: 9242902]
42. Yang H, Jeffrey PD, Miller J, et al. BRCA2 function in DNA binding and recombination from a
BRCA2-DSS1-ssDNA structure. Science. 2002; 297:1837–1848. [PubMed: 12228710]
43. Li Y, Bolderson E, Kumar R, et al. HSSB1 and hSSB2 form similar multiprotein complexes that
participate in DNA damage response. J Biol Chem. 2009; 284:23525–23531. [PubMed: 19605351]
44. Broderick S, Rehmet K, Concannon C, et al. Eukaryotic single-stranded DNA binding proteins:
central factors in genome stability. Subcell Biochem. 2010; 50:143–163. [PubMed: 20012581]
45. Panagiotou OA, Ioannidis JP. What should the genome-wide significance threshold be? Empirical
replication of borderline genetic associations. Int J Epidemiol. 2012; 41:273–286. [PubMed:
22253303]
46. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev
Cancer. 2003; 3:422–433. [PubMed: 12778132]
47. Turck N, Gross I, Gendry P, et al. Laminin isoforms: biological roles and effects on the
intracellular distribution of nuclear proteins in intestinal epithelial cells. Exp Cell Res. 2005;
303:494–503. [PubMed: 15652360]
48. Pouliot N, Saunders NA, Kaur P. Laminin 10/11: an alternative adhesive ligand for epidermal
keratinocytes with a functional role in promoting proliferation and migration. Exp Dermatol. 2002;
11:387–397. [PubMed: 12366691]
49. Gudjonsson T, Ronnov-Jessen L, Villadsen R, et al. Normal and tumor-derived myoepithelial cells
differ in their ability to interact with luminal breast epithelial cells for polarity and basement
membrane deposition. J Cell Sci. 2002; 115:39–50. [PubMed: 11801722]
50. Patarroyo M, Tryggvason K, Virtanen I. Laminin isoforms in tumor invasion, angiogenesis and
metastasis. Semin Cancer Biol. 2002; 12:197–207. [PubMed: 12083850]
51. Akhavan A, Griffith OL, Soroceanu L, et al. Loss of cell-surface laminin anchoring promotes
tumor growth and is associated with poor clinical outcomes. Cancer Res. 2012; 72:2578–2588.
[PubMed: 22589276]
52. Lukas J, Muller H, Bartkova J, et al. DNA tumor virus oncoproteins and retinoblastoma gene
mutations share the ability to relieve the cell’s requirement for cyclin D1 function in G1. J Cell
Biol. 1994; 125:625–638. [PubMed: 8175885]
53. Matsushime H, Quelle DE, Shurtleff SA, et al. D-type cyclin-dependent kinase activity in
mammalian cells. Mol Cell Biol. 1994; 14:2066–2076. [PubMed: 8114738]
54. Ragusa M, Statello L, Maugeri M, et al. Specific alterations of the microRNA transcriptome and
global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors. J Mol
Med (Berl). 2012; 90:1421–1438. [PubMed: 22660396]
Peters et al. Page 14
Gastroenterology. Author manuscript; available in PMC 2014 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
55. Zhang P, Ma Y, Wang F, et al. Comprehensive gene and microRNA expression profiling reveals
the crucial role of hsa-let-7i and its target genes in colorectal cancer metastasis. Mol Biol Rep.
2012; 39:1471–1478. [PubMed: 21625861]
56. Yang Y, Wang F, Shi C, et al. Cyclin D1 G870A polymorphism contributes to colorectal cancer
susceptibility: evidence from a systematic review of 22 case-control studies. PLoS One. 2012;
7:e36813. [PubMed: 22606291]
57. Yang J, Zhang G, Chen J. CCND1 G870A polymorphism is associated with increased risk of
colorectal cancer, especially for sporadic colorectal cancer and in Caucasians: a meta-analysis.
Clin Res Hepatol Gastroenterol. 2012; 36:169–177. [PubMed: 22322158]
58. Turnbull C, Rapley EA, Seal S, et al. Variants near DMRT1, TERT and ATF7IP are associated
with testicular germ cell cancer. Nat Genet. 2010; 42:604–607. [PubMed: 20543847]
59. Smith J, Mowla S, Prince S. Basal transcription of the human TBX3 gene, a key developmental
regulator which is overexpressed in several cancers, requires functional NF-Y and Sp1 sites. Gene.
2011; 486:41–46. [PubMed: 21784138]
60. Washkowitz AJ, Gavrilov S, Begum S, et al. Diverse functional networks of Tbx3 in development
and disease. Wiley Interdiscip Rev Syst Biol Med. 2012; 4:273–283. [PubMed: 22334480]
61. Renard CA, Labalette C, Armengol C, et al. Tbx3 is a downstream target of the Wnt/beta-catenin
pathway and a critical mediator of beta-catenin survival functions in liver cancer. Cancer Res.
2007; 67:901–910. [PubMed: 17283120]
62. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by
mutations in beta-catenin or APC. Science. 1997; 275:1787–1790. [PubMed: 9065402]
63. Yu J, Ma X, Cheung KF, et al. Epigenetic inactivation of T-box transcription factor 5, a novel
tumor suppressor gene, is associated with colon cancer. Oncogene. 2010; 29:6464–6474.
[PubMed: 20802524]
64. Garner C. Upward bias in odds ratio estimates from genome-wide association studies. Genet
Epidemiol. 2007; 31:288–295. [PubMed: 17266119]
65. Setiawan VW, Haessler J, Schumacher F, et al. HNF1B and endometrial cancer risk: results from
the PAGE study. PLoS One. 2012; 7:e30390. [PubMed: 22299039]
66. Lindstrom S, Schumacher FR, Campa D, et al. Replication of five prostate cancer loci identified in
an Asian population–results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3).
Cancer Epidemiol Biomarkers Prev. 2012; 21:212–216. [PubMed: 22056501]
67. Dumitrescu L, Carty CL, Taylor K, et al. Genetic determinants of lipid traits in diverse populations
from the population architecture using genomics and epidemiology (PAGE) study. PLoS Genet.
2011; 7:e1002138. [PubMed: 21738485]
68. Buyske S, Wu Y, Carty CL, et al. Evaluation of the metabochip genotyping array in African
Americans and implications for fine mapping of GWAS-identified loci: the PAGE study. PLoS
One. 2012; 7:e35651. [PubMed: 22539988]
69. Pritchard JK, Przeworski M. Linkage disequilibrium in humans: models and data. Am J Hum
Genet. 2001; 69:1–14. [PubMed: 11410837]
70. Newton-Cheh CN, Eijgelsheim M, Rice KM, et al. Common variants at ten loci infuence QT
interval duration in the QTGEN Study. Nat Genet. 2009; 41:399–406. [PubMed: 19305408]
Peters et al. Page 15
Gastroenterology. Author manuscript; available in PMC 2014 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Peters et al. Page 16
Ta
bl
e 
1
R
isk
 E
sti
m
at
es
 fo
r N
ew
ly
 Id
en
tif
ie
d 
SN
Ps
 A
ss
oc
ia
te
d 
W
ith
 C
ol
or
ec
ta
l C
an
ce
r a
t a
 P
 
V
al
ue
 L
es
s T
ha
n 
5 
× 
10
−
7
SN
P
C
hr
om
os
om
e
(ge
ne
)a
R
isk
a
lle
le
St
ag
eb
R
A
F 
(ra
ng
e)c
O
R
 (9
5%
 C
I)
P 
v
a
lu
e
P 
he
te
ro
ge
ne
ity
SN
P 
w
ith
 P
 
<
 5
 ×
 1
0−
8
 
 
rs
11
90
37
57
2q
32
.3
 (N
A
BP
1)
C
G
W
A
S
0.
16
 (0
.11
–0
.23
)
1.
15
 (1
.09
–1
.22
)
1.
38
E-
06
A
sia
n
0.
05
 (0
.04
–0
.08
)
1.
16
 (0
.95
–1
.41
)
1.
34
E-
01
A
de
no
m
a
0.
15
1.
23
 (1
.03
–1
.47
)
2.
30
E-
02
O
ve
ra
ll
1.
16
 (1
.10
–1
.22
)
3.
71
E-
08
.
27
SN
Ps
 w
ith
 P
 
<
 5
 ×
 1
0−
7 a
n
d 
P 
>
 5
 ×
 1
0−
8
 
 
rs
10
91
12
51
1q
25
.3
 (L
A
M
C1
)
A
G
W
A
S
0.
57
 (0
.49
–0
.63
)
1.
10
 (1
.06
–1
.14
)
1.
34
E-
06
A
sia
n
0.
54
 (0
.50
–0
.55
)
1.
09
 (1
.01
–1
.17
)
3.
20
E-
02
A
de
no
m
a
0.
58
1.
06
 (0
.93
–1
.21
)
3.
66
E-
01
O
ve
ra
ll
1.
09
 (1
.06
–1
.13
)
9.
45
E-
08
.
69
 
 
rs
32
17
81
0
12
p1
3.
32
 (C
CN
D2
)
T
G
W
A
S
0.
16
 (0
.18
–0
.10
)
1.
19
 (1
.11
–1
.28
)
3.
40
E-
07
A
sia
n
N
A
N
A
N
A
A
de
no
m
a
0.
15
1.
31
 (1
.00
–1
.71
)
5.
07
E-
02
O
ve
ra
ll
1.
20
 (1
.12
–1
.28
)
5.
86
E-
08
.
91
 
 
rs
32
17
90
1
12
p1
3.
32
 (C
CN
D2
)
G
G
W
A
S
0.
41
 (0
.43
–0
.39
)
1.
10
 (1
.06
–1
.15
)
1.
71
E-
06
A
sia
n
0.
56
 (0
.54
–0
.58
)
1.
08
 (0
.98
–1
.18
)
1.
04
E-
01
A
de
no
m
a
0.
42
1.
08
 (0
.91
–1
.27
)
3.
72
E-
01
O
ve
ra
ll
1.
10
 (1
.06
–1
.14
)
3.
31
E-
07
.
51
 
 
rs
59
33
6
12
q2
4.
21
 (T
BX
3)
T
G
W
A
S
0.
48
 (0
.51
–0
.42
)
1.
10
 (1
.06
–1
.14
)
7.
64
E-
07
A
sia
n
0.
60
 (0
.56
–0
.62
)
1.
05
 (0
.94
–1
.18
)
3.
61
E-
01
A
de
no
m
a
0.
48
1.
13
 (0
.90
–1
.40
)
2.
89
E-
01
O
ve
ra
ll
1.
09
 (1
.06
–1
.13
)
3.
67
E-
07
.
39
CI
, c
on
fid
en
ce
 in
te
rv
al
; R
A
F,
 ri
sk
 a
lle
le
 fr
eq
ue
nc
y.
N
O
TE
. B
ol
de
d 
en
tri
es
 si
gn
ify
 c
om
bi
ne
d 
re
su
lts
.
a C
hr
om
os
om
e 
po
sit
io
n 
an
d 
bu
ild
 fr
om
 G
en
om
e 
Br
ow
se
r b
as
ed
 o
n 
bu
ild
 3
7.
b G
W
A
S 
(n 
= 1
2,6
96
 ca
ses
 an
d 1
5,1
13
 co
ntr
ols
); 
As
ian
 (2
09
8 c
ase
s a
nd
 57
49
 co
ntr
ols
); 
ad
en
om
a (
95
8 c
ase
s a
nd
 90
9 c
on
tro
ls)
; o
ve
ral
l (
15
,75
2 c
ase
s a
nd
 21
,77
1 c
on
tro
ls 
ex
ce
pt 
for
 rs
32
17
81
0, 
wh
ich
 ha
s
13
,6
54
 ca
se
s a
nd
 1
6,
02
2 
co
nt
ro
ls)
.
Gastroenterology. Author manuscript; available in PMC 2014 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Peters et al. Page 17
c M
ea
n 
an
d 
(ra
ng
e) 
co
mp
ute
d f
rom
 re
sp
ec
tiv
e s
tud
ies
.
Gastroenterology. Author manuscript; available in PMC 2014 April 01.
